Upcoming

2023

Disease-modifying Agents Market

Disease-Modifying Agents Market

by Drug Class (Interferon Beta-1?/?, Natalizumab, Mitoxantrone, Glatiramer Acetate, Fingolimod, Dimethyl Fumarate, Ocrelizumab, Teriflunomide, Ciclosporin, Cyclophosphamide, Hydroxychloroquine, Leflunomide, Methotrexate, Mycophenolate, Sulfasalazine, Others), by Indication (Multiple Sclerosis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Sclerosis, Cancer, Others), by Therapy Type (Monotherapy, Combination therapy), by Route of Administration (Oral, Infusion, Subcutaneous, Intravenous) and by End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Medical Devices & Supplies	Report Code: A12016	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Disease-modifying Agents Market

Request Now !

Disease modification can be defined as treatments that affect the underlying pathophysiology of the disease and have a beneficial outcome. In the struggle to decrease the development of disease in many inflammatory conditions such as rheumatoid arthritis, psoriasis, and psoriatic arthritis, multiple sclerosis, and Crohn's disease, the disease-modifying agent class, including treatments such as anti-TNF agents and immunomodulators, averting the progression of each disease and also the market is experiencing notable growth. However, the landscape has changed with the entry of disease-modifying agents. Several new disease-modifying drugs are in the line, all of which will offer important options for patients with these diseases, thus promoting the growth of the disease-modifying agents market.

COVID-19 Impact analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the disease-modifying agents market.

Top Impacting Factors

Increase in cases of inflammatory diseases, surge in geriatric population, rise in demand for minimally invasive procedure & advanced treatments such as disease modifying agents are the factors that drive the growth of the disease modifying agents market.
Disease-modifying anti-rheumatic agents work to suppress the body's overactive immune and/or inflammatory systems; anti-TNFs are extremely effective treatments; disease-modifying agents are also effective for osteoarthritis; however, the agents are still under the clinical trial phase. Limited availability of products is anticipated to provide a lucrative opportunity to launch disease-modifying agents in the market.
Few factors expected to hinder the growth of the disease modifying agents market include drug recalls by the FDA and EMA and increase in cost of multiple sclerosis disease-modifying agents.

Market Trends

Promising Product Pipeline Expected to Flourish the Market

Companies are taking efforts to develop therapeutic modalities for underlying pathophysiological changes in Alzheimer’s disease and other neurodegenerative disorders.

A phase 3 study of isradipine is being carried out as a disease-modifying agent in patients with early Parkinson's disease by STEADY-PD III, funded by National Institute of Neurological Disorders and Stroke (NINDS).

In September 2020, Prothena Corporation plc declared the results of the Phase 2 PASADENA study of prasinezumab, which is the first anti-inflammatory, anti-alpha-synuclein antibody to show efficacy in patients with early Parkinson's disease.

Key Benefits of the Report

This study presents the analytical depiction of the disease-modifying agents industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the disease-modifying agents market share.
The current market is quantitatively analyzed to highlight the disease-modifying agents market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed disease-modifying agents market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the disease-modifying agents Report

Who are the leading players active in the gamete preservation market?
What are the current trends that will influence the market in the next few years?
What is "Disease-modifying agents "?
What is "Disease-modifying agents" Market prediction in the future?
Who are the leading global players in the "Disease-modifying agents" Market?

Disease-Modifying Agents Market Report Highlights

Aspects	Details
By Drug Class	Interferon Beta-1α/β Natalizumab Mitoxantrone Glatiramer Acetate Fingolimod Dimethyl Fumarate Ocrelizumab Teriflunomide Ciclosporin Cyclophosphamide Hydroxychloroquine Leflunomide Methotrexate Mycophenolate Sulfasalazine Others
By Indication	Multiple Sclerosis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Systemic Sclerosis Cancer Others
By Therapy Type	Monotherapy Combination therapy
By Route of Administration	Oral Infusion Subcutaneous Intravenous
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
By End User	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
Key Market Players	Biogen Inc., Accord Healthcare Inc, Nordic Group Bv, Antares Pharma, Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Hospira, Inc., Fresenius Kabi, Pfizer Inc, Elan Pharma India Pvt Ltd.

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Drug Class
- 4.2. Interferon Beta-1α/β
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Natalizumab
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
- 4.4. Mitoxantrone
  - 4.4.1. Key Market Trends, Growth Factors and Opportunities
  - 4.4.2. Market Size and Forecast, By Region
  - 4.4.3. Market Share Analysis, By Country
- 4.5. Glatiramer Acetate
  - 4.5.1. Key Market Trends, Growth Factors and Opportunities
  - 4.5.2. Market Size and Forecast, By Region
  - 4.5.3. Market Share Analysis, By Country
- 4.6. Fingolimod
  - 4.6.1. Key Market Trends, Growth Factors and Opportunities
  - 4.6.2. Market Size and Forecast, By Region
  - 4.6.3. Market Share Analysis, By Country
- 4.7. Dimethyl Fumarate
  - 4.7.1. Key Market Trends, Growth Factors and Opportunities
  - 4.7.2. Market Size and Forecast, By Region
  - 4.7.3. Market Share Analysis, By Country
- 4.8. Ocrelizumab
  - 4.8.1. Key Market Trends, Growth Factors and Opportunities
  - 4.8.2. Market Size and Forecast, By Region
  - 4.8.3. Market Share Analysis, By Country
- 4.9. Teriflunomide
  - 4.9.1. Key Market Trends, Growth Factors and Opportunities
  - 4.9.2. Market Size and Forecast, By Region
  - 4.9.3. Market Share Analysis, By Country
- 4.10. Ciclosporin
  - 4.10.1. Key Market Trends, Growth Factors and Opportunities
  - 4.10.2. Market Size and Forecast, By Region
  - 4.10.3. Market Share Analysis, By Country
- 4.11. Cyclophosphamide
  - 4.11.1. Key Market Trends, Growth Factors and Opportunities
  - 4.11.2. Market Size and Forecast, By Region
  - 4.11.3. Market Share Analysis, By Country
- 4.12. Hydroxychloroquine
  - 4.12.1. Key Market Trends, Growth Factors and Opportunities
  - 4.12.2. Market Size and Forecast, By Region
  - 4.12.3. Market Share Analysis, By Country
- 4.13. Leflunomide
  - 4.13.1. Key Market Trends, Growth Factors and Opportunities
  - 4.13.2. Market Size and Forecast, By Region
  - 4.13.3. Market Share Analysis, By Country
- 4.14. Methotrexate
  - 4.14.1. Key Market Trends, Growth Factors and Opportunities
  - 4.14.2. Market Size and Forecast, By Region
  - 4.14.3. Market Share Analysis, By Country
- 4.15. Mycophenolate
  - 4.15.1. Key Market Trends, Growth Factors and Opportunities
  - 4.15.2. Market Size and Forecast, By Region
  - 4.15.3. Market Share Analysis, By Country
- 4.16. Sulfasalazine
  - 4.16.1. Key Market Trends, Growth Factors and Opportunities
  - 4.16.2. Market Size and Forecast, By Region
  - 4.16.3. Market Share Analysis, By Country
- 4.17. Others
  - 4.17.1. Key Market Trends, Growth Factors and Opportunities
  - 4.17.2. Market Size and Forecast, By Region
  - 4.17.3. Market Share Analysis, By Country
CHAPTER 5: DISEASE-MODIFYING AGENTS MARKET, BY INDICATION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Indication
- 5.2. Multiple Sclerosis
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Rheumatoid Arthritis
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Psoriatic Arthritis
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Ankylosing Spondylitis
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country
- 5.6. Systemic Sclerosis
  - 5.6.1. Key Market Trends, Growth Factors and Opportunities
  - 5.6.2. Market Size and Forecast, By Region
  - 5.6.3. Market Share Analysis, By Country
- 5.7. Cancer
  - 5.7.1. Key Market Trends, Growth Factors and Opportunities
  - 5.7.2. Market Size and Forecast, By Region
  - 5.7.3. Market Share Analysis, By Country
- 5.8. Others
  - 5.8.1. Key Market Trends, Growth Factors and Opportunities
  - 5.8.2. Market Size and Forecast, By Region
  - 5.8.3. Market Share Analysis, By Country
CHAPTER 6: DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Therapy Type
- 6.2. Monotherapy
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Combination Therapy
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
CHAPTER 7: DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By Route Of Administration
- 7.2. Oral
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Infusion
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Subcutaneous
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country
- 7.5. Intravenous
  - 7.5.1. Key Market Trends, Growth Factors and Opportunities
  - 7.5.2. Market Size and Forecast, By Region
  - 7.5.3. Market Share Analysis, By Country
CHAPTER 8: DISEASE-MODIFYING AGENTS MARKET, BY END USER
- 8.1. Market Overview
  - 8.1.1 Market Size and Forecast, By End User
- 8.2. Hospital Pharmacies
  - 8.2.1. Key Market Trends, Growth Factors and Opportunities
  - 8.2.2. Market Size and Forecast, By Region
  - 8.2.3. Market Share Analysis, By Country
- 8.3. Retail Pharmacies
  - 8.3.1. Key Market Trends, Growth Factors and Opportunities
  - 8.3.2. Market Size and Forecast, By Region
  - 8.3.3. Market Share Analysis, By Country
- 8.4. Online Pharmacies
  - 8.4.1. Key Market Trends, Growth Factors and Opportunities
  - 8.4.2. Market Size and Forecast, By Region
  - 8.4.3. Market Share Analysis, By Country
- 8.5. Others
  - 8.5.1. Key Market Trends, Growth Factors and Opportunities
  - 8.5.2. Market Size and Forecast, By Region
  - 8.5.3. Market Share Analysis, By Country
CHAPTER 9: DISEASE-MODIFYING AGENTS MARKET, BY REGION
- 9.1. Market Overview
  - 9.1.1 Market Size and Forecast, By Region
- 9.2. North America
  - 9.2.1. Key Market Trends and Opportunities
  - 9.2.2. Market Size and Forecast, By Drug Class
  - 9.2.3. Market Size and Forecast, By Indication
  - 9.2.4. Market Size and Forecast, By Therapy Type
  - 9.2.5. Market Size and Forecast, By Route Of Administration
  - 9.2.6. Market Size and Forecast, By End User
  - 9.2.7. Market Size and Forecast, By Country
  - 9.2.8. U.S. Disease-modifying Agents Market
    - 9.2.8.1. Market Size and Forecast, By Drug Class
    - 9.2.8.2. Market Size and Forecast, By Indication
    - 9.2.8.3. Market Size and Forecast, By Therapy Type
    - 9.2.8.4. Market Size and Forecast, By Route Of Administration
    - 9.2.8.5. Market Size and Forecast, By End User
  - 9.2.9. Canada Disease-modifying Agents Market
    - 9.2.9.1. Market Size and Forecast, By Drug Class
    - 9.2.9.2. Market Size and Forecast, By Indication
    - 9.2.9.3. Market Size and Forecast, By Therapy Type
    - 9.2.9.4. Market Size and Forecast, By Route Of Administration
    - 9.2.9.5. Market Size and Forecast, By End User
  - 9.2.10. Mexico Disease-modifying Agents Market
    - 9.2.10.1. Market Size and Forecast, By Drug Class
    - 9.2.10.2. Market Size and Forecast, By Indication
    - 9.2.10.3. Market Size and Forecast, By Therapy Type
    - 9.2.10.4. Market Size and Forecast, By Route Of Administration
    - 9.2.10.5. Market Size and Forecast, By End User
- 9.3. Europe
  - 9.3.1. Key Market Trends and Opportunities
  - 9.3.2. Market Size and Forecast, By Drug Class
  - 9.3.3. Market Size and Forecast, By Indication
  - 9.3.4. Market Size and Forecast, By Therapy Type
  - 9.3.5. Market Size and Forecast, By Route Of Administration
  - 9.3.6. Market Size and Forecast, By End User
  - 9.3.7. Market Size and Forecast, By Country
  - 9.3.8. France Disease-modifying Agents Market
    - 9.3.8.1. Market Size and Forecast, By Drug Class
    - 9.3.8.2. Market Size and Forecast, By Indication
    - 9.3.8.3. Market Size and Forecast, By Therapy Type
    - 9.3.8.4. Market Size and Forecast, By Route Of Administration
    - 9.3.8.5. Market Size and Forecast, By End User
  - 9.3.9. Germany Disease-modifying Agents Market
    - 9.3.9.1. Market Size and Forecast, By Drug Class
    - 9.3.9.2. Market Size and Forecast, By Indication
    - 9.3.9.3. Market Size and Forecast, By Therapy Type
    - 9.3.9.4. Market Size and Forecast, By Route Of Administration
    - 9.3.9.5. Market Size and Forecast, By End User
  - 9.3.10. Italy Disease-modifying Agents Market
    - 9.3.10.1. Market Size and Forecast, By Drug Class
    - 9.3.10.2. Market Size and Forecast, By Indication
    - 9.3.10.3. Market Size and Forecast, By Therapy Type
    - 9.3.10.4. Market Size and Forecast, By Route Of Administration
    - 9.3.10.5. Market Size and Forecast, By End User
  - 9.3.11. Spain Disease-modifying Agents Market
    - 9.3.11.1. Market Size and Forecast, By Drug Class
    - 9.3.11.2. Market Size and Forecast, By Indication
    - 9.3.11.3. Market Size and Forecast, By Therapy Type
    - 9.3.11.4. Market Size and Forecast, By Route Of Administration
    - 9.3.11.5. Market Size and Forecast, By End User
  - 9.3.12. UK Disease-modifying Agents Market
    - 9.3.12.1. Market Size and Forecast, By Drug Class
    - 9.3.12.2. Market Size and Forecast, By Indication
    - 9.3.12.3. Market Size and Forecast, By Therapy Type
    - 9.3.12.4. Market Size and Forecast, By Route Of Administration
    - 9.3.12.5. Market Size and Forecast, By End User
  - 9.3.13. Russia Disease-modifying Agents Market
    - 9.3.13.1. Market Size and Forecast, By Drug Class
    - 9.3.13.2. Market Size and Forecast, By Indication
    - 9.3.13.3. Market Size and Forecast, By Therapy Type
    - 9.3.13.4. Market Size and Forecast, By Route Of Administration
    - 9.3.13.5. Market Size and Forecast, By End User
  - 9.3.14. Rest Of Europe Disease-modifying Agents Market
    - 9.3.14.1. Market Size and Forecast, By Drug Class
    - 9.3.14.2. Market Size and Forecast, By Indication
    - 9.3.14.3. Market Size and Forecast, By Therapy Type
    - 9.3.14.4. Market Size and Forecast, By Route Of Administration
    - 9.3.14.5. Market Size and Forecast, By End User
- 9.4. Asia-Pacific
  - 9.4.1. Key Market Trends and Opportunities
  - 9.4.2. Market Size and Forecast, By Drug Class
  - 9.4.3. Market Size and Forecast, By Indication
  - 9.4.4. Market Size and Forecast, By Therapy Type
  - 9.4.5. Market Size and Forecast, By Route Of Administration
  - 9.4.6. Market Size and Forecast, By End User
  - 9.4.7. Market Size and Forecast, By Country
  - 9.4.8. China Disease-modifying Agents Market
    - 9.4.8.1. Market Size and Forecast, By Drug Class
    - 9.4.8.2. Market Size and Forecast, By Indication
    - 9.4.8.3. Market Size and Forecast, By Therapy Type
    - 9.4.8.4. Market Size and Forecast, By Route Of Administration
    - 9.4.8.5. Market Size and Forecast, By End User
  - 9.4.9. Japan Disease-modifying Agents Market
    - 9.4.9.1. Market Size and Forecast, By Drug Class
    - 9.4.9.2. Market Size and Forecast, By Indication
    - 9.4.9.3. Market Size and Forecast, By Therapy Type
    - 9.4.9.4. Market Size and Forecast, By Route Of Administration
    - 9.4.9.5. Market Size and Forecast, By End User
  - 9.4.10. India Disease-modifying Agents Market
    - 9.4.10.1. Market Size and Forecast, By Drug Class
    - 9.4.10.2. Market Size and Forecast, By Indication
    - 9.4.10.3. Market Size and Forecast, By Therapy Type
    - 9.4.10.4. Market Size and Forecast, By Route Of Administration
    - 9.4.10.5. Market Size and Forecast, By End User
  - 9.4.11. South Korea Disease-modifying Agents Market
    - 9.4.11.1. Market Size and Forecast, By Drug Class
    - 9.4.11.2. Market Size and Forecast, By Indication
    - 9.4.11.3. Market Size and Forecast, By Therapy Type
    - 9.4.11.4. Market Size and Forecast, By Route Of Administration
    - 9.4.11.5. Market Size and Forecast, By End User
  - 9.4.12. Australia Disease-modifying Agents Market
    - 9.4.12.1. Market Size and Forecast, By Drug Class
    - 9.4.12.2. Market Size and Forecast, By Indication
    - 9.4.12.3. Market Size and Forecast, By Therapy Type
    - 9.4.12.4. Market Size and Forecast, By Route Of Administration
    - 9.4.12.5. Market Size and Forecast, By End User
  - 9.4.13. Thailand Disease-modifying Agents Market
    - 9.4.13.1. Market Size and Forecast, By Drug Class
    - 9.4.13.2. Market Size and Forecast, By Indication
    - 9.4.13.3. Market Size and Forecast, By Therapy Type
    - 9.4.13.4. Market Size and Forecast, By Route Of Administration
    - 9.4.13.5. Market Size and Forecast, By End User
  - 9.4.14. Malaysia Disease-modifying Agents Market
    - 9.4.14.1. Market Size and Forecast, By Drug Class
    - 9.4.14.2. Market Size and Forecast, By Indication
    - 9.4.14.3. Market Size and Forecast, By Therapy Type
    - 9.4.14.4. Market Size and Forecast, By Route Of Administration
    - 9.4.14.5. Market Size and Forecast, By End User
  - 9.4.15. Indonesia Disease-modifying Agents Market
    - 9.4.15.1. Market Size and Forecast, By Drug Class
    - 9.4.15.2. Market Size and Forecast, By Indication
    - 9.4.15.3. Market Size and Forecast, By Therapy Type
    - 9.4.15.4. Market Size and Forecast, By Route Of Administration
    - 9.4.15.5. Market Size and Forecast, By End User
  - 9.4.16. Rest of Asia Pacific Disease-modifying Agents Market
    - 9.4.16.1. Market Size and Forecast, By Drug Class
    - 9.4.16.2. Market Size and Forecast, By Indication
    - 9.4.16.3. Market Size and Forecast, By Therapy Type
    - 9.4.16.4. Market Size and Forecast, By Route Of Administration
    - 9.4.16.5. Market Size and Forecast, By End User
- 9.5. LAMEA
  - 9.5.1. Key Market Trends and Opportunities
  - 9.5.2. Market Size and Forecast, By Drug Class
  - 9.5.3. Market Size and Forecast, By Indication
  - 9.5.4. Market Size and Forecast, By Therapy Type
  - 9.5.5. Market Size and Forecast, By Route Of Administration
  - 9.5.6. Market Size and Forecast, By End User
  - 9.5.7. Market Size and Forecast, By Country
  - 9.5.8. Brazil Disease-modifying Agents Market
    - 9.5.8.1. Market Size and Forecast, By Drug Class
    - 9.5.8.2. Market Size and Forecast, By Indication
    - 9.5.8.3. Market Size and Forecast, By Therapy Type
    - 9.5.8.4. Market Size and Forecast, By Route Of Administration
    - 9.5.8.5. Market Size and Forecast, By End User
  - 9.5.9. South Africa Disease-modifying Agents Market
    - 9.5.9.1. Market Size and Forecast, By Drug Class
    - 9.5.9.2. Market Size and Forecast, By Indication
    - 9.5.9.3. Market Size and Forecast, By Therapy Type
    - 9.5.9.4. Market Size and Forecast, By Route Of Administration
    - 9.5.9.5. Market Size and Forecast, By End User
  - 9.5.10. Saudi Arabia Disease-modifying Agents Market
    - 9.5.10.1. Market Size and Forecast, By Drug Class
    - 9.5.10.2. Market Size and Forecast, By Indication
    - 9.5.10.3. Market Size and Forecast, By Therapy Type
    - 9.5.10.4. Market Size and Forecast, By Route Of Administration
    - 9.5.10.5. Market Size and Forecast, By End User
  - 9.5.11. UAE Disease-modifying Agents Market
    - 9.5.11.1. Market Size and Forecast, By Drug Class
    - 9.5.11.2. Market Size and Forecast, By Indication
    - 9.5.11.3. Market Size and Forecast, By Therapy Type
    - 9.5.11.4. Market Size and Forecast, By Route Of Administration
    - 9.5.11.5. Market Size and Forecast, By End User
  - 9.5.12. Argentina Disease-modifying Agents Market
    - 9.5.12.1. Market Size and Forecast, By Drug Class
    - 9.5.12.2. Market Size and Forecast, By Indication
    - 9.5.12.3. Market Size and Forecast, By Therapy Type
    - 9.5.12.4. Market Size and Forecast, By Route Of Administration
    - 9.5.12.5. Market Size and Forecast, By End User
  - 9.5.13. Rest of LAMEA Disease-modifying Agents Market
    - 9.5.13.1. Market Size and Forecast, By Drug Class
    - 9.5.13.2. Market Size and Forecast, By Indication
    - 9.5.13.3. Market Size and Forecast, By Therapy Type
    - 9.5.13.4. Market Size and Forecast, By Route Of Administration
    - 9.5.13.5. Market Size and Forecast, By End User
CHAPTER 10: COMPETITIVE LANDSCAPE
- 10.1. Introduction
- 10.2. Top Winning Strategies
- 10.3. Product Mapping Of Top 10 Player
- 10.4. Competitive Dashboard
- 10.5. Competitive Heatmap
- 10.6. Top Player Positioning,2022
CHAPTER 11: COMPANY PROFILES
- 11.1. Biogen Inc.
  - 11.1.1. Company Overview
  - 11.1.2. Key Executives
  - 11.1.3. Company Snapshot
  - 11.1.4. Operating Business Segments
  - 11.1.5. Product Portfolio
  - 11.1.6. Business Performance
  - 11.1.7. Key Strategic Moves and Developments
- 11.2. Merck KGaA
  - 11.2.1. Company Overview
  - 11.2.2. Key Executives
  - 11.2.3. Company Snapshot
  - 11.2.4. Operating Business Segments
  - 11.2.5. Product Portfolio
  - 11.2.6. Business Performance
  - 11.2.7. Key Strategic Moves and Developments
- 11.3. Elan Pharma India Pvt Ltd.
  - 11.3.1. Company Overview
  - 11.3.2. Key Executives
  - 11.3.3. Company Snapshot
  - 11.3.4. Operating Business Segments
  - 11.3.5. Product Portfolio
  - 11.3.6. Business Performance
  - 11.3.7. Key Strategic Moves and Developments
- 11.4. Fresenius Kabi
  - 11.4.1. Company Overview
  - 11.4.2. Key Executives
  - 11.4.3. Company Snapshot
  - 11.4.4. Operating Business Segments
  - 11.4.5. Product Portfolio
  - 11.4.6. Business Performance
  - 11.4.7. Key Strategic Moves and Developments
- 11.5. Pfizer Inc
  - 11.5.1. Company Overview
  - 11.5.2. Key Executives
  - 11.5.3. Company Snapshot
  - 11.5.4. Operating Business Segments
  - 11.5.5. Product Portfolio
  - 11.5.6. Business Performance
  - 11.5.7. Key Strategic Moves and Developments
- 11.6. Teva Pharmaceutical Industries Ltd.
  - 11.6.1. Company Overview
  - 11.6.2. Key Executives
  - 11.6.3. Company Snapshot
  - 11.6.4. Operating Business Segments
  - 11.6.5. Product Portfolio
  - 11.6.6. Business Performance
  - 11.6.7. Key Strategic Moves and Developments
- 11.7. Hospira, Inc.
  - 11.7.1. Company Overview
  - 11.7.2. Key Executives
  - 11.7.3. Company Snapshot
  - 11.7.4. Operating Business Segments
  - 11.7.5. Product Portfolio
  - 11.7.6. Business Performance
  - 11.7.7. Key Strategic Moves and Developments
- 11.8. Accord Healthcare Inc
  - 11.8.1. Company Overview
  - 11.8.2. Key Executives
  - 11.8.3. Company Snapshot
  - 11.8.4. Operating Business Segments
  - 11.8.5. Product Portfolio
  - 11.8.6. Business Performance
  - 11.8.7. Key Strategic Moves and Developments
- 11.9. Nordic Group Bv
  - 11.9.1. Company Overview
  - 11.9.2. Key Executives
  - 11.9.3. Company Snapshot
  - 11.9.4. Operating Business Segments
  - 11.9.5. Product Portfolio
  - 11.9.6. Business Performance
  - 11.9.7. Key Strategic Moves and Developments
- 11.10. Antares Pharma, Inc.
  - 11.10.1. Company Overview
  - 11.10.2. Key Executives
  - 11.10.3. Company Snapshot
  - 11.10.4. Operating Business Segments
  - 11.10.5. Product Portfolio
  - 11.10.6. Business Performance
  - 11.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 2. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INTERFERON BETA-1α/β, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR NATALIZUMAB, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MITOXANTRONE, BY REGION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR GLATIRAMER ACETATE, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR FINGOLIMOD, BY REGION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR DIMETHYL FUMARATE, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OCRELIZUMAB, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR TERIFLUNOMIDE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CICLOSPORIN, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CYCLOPHOSPHAMIDE, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR HYDROXYCHLOROQUINE, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR LEFLUNOMIDE, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR METHOTREXATE, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MYCOPHENOLATE, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SULFASALAZINE, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 19. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 20. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 21. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR PSORIATIC ARTHRITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 22. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ANKYLOSING SPONDYLITIS, BY REGION, 2022-2032 ($MILLION)
TABLE 23. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SYSTEMIC SCLEROSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 24. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 25. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 26. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 27. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR MONOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 28. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR COMBINATION THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 29. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 30. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 31. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INFUSION, BY REGION, 2022-2032 ($MILLION)
TABLE 32. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR SUBCUTANEOUS, BY REGION, 2022-2032 ($MILLION)
TABLE 33. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR INTRAVENOUS, BY REGION, 2022-2032 ($MILLION)
TABLE 34. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 35. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 36. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 37. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 38. GLOBAL DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 39. GLOBAL DISEASE-MODIFYING AGENTS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 40. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 41. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 42. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 43. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 44. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 45. NORTH AMERICA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 46. U.S. DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 47. U.S. DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48. U.S. DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 49. U.S. DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. U.S. DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 51. CANADA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 52. CANADA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 53. CANADA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 54. CANADA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 55. CANADA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 56. MEXICO DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 57. MEXICO DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 58. MEXICO DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 59. MEXICO DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. MEXICO DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 61. EUROPE DISEASE-MODIFYING AGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 62. EUROPE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 63. EUROPE DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 64. EUROPE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 65. EUROPE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. EUROPE DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 67. FRANCE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 68. FRANCE DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 69. FRANCE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 70. FRANCE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. FRANCE DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 72. GERMANY DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 73. GERMANY DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 74. GERMANY DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 75. GERMANY DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 76. GERMANY DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 77. ITALY DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 78. ITALY DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 79. ITALY DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 80. ITALY DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 81. ITALY DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 82. SPAIN DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 83. SPAIN DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 84. SPAIN DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 85. SPAIN DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 86. SPAIN DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 87. UK DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 88. UK DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 89. UK DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 90. UK DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 91. UK DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 92. RUSSIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 93. RUSSIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 94. RUSSIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 95. RUSSIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 96. RUSSIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 97. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 98. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 99. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 100. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 101. REST OF EUROPE DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 102. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 103. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 104. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 105. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 106. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 107. ASIA-PACIFIC DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 108. CHINA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 109. CHINA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 110. CHINA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 111. CHINA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 112. CHINA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 113. JAPAN DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 114. JAPAN DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 115. JAPAN DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 116. JAPAN DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 117. JAPAN DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 118. INDIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 119. INDIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 120. INDIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 121. INDIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 122. INDIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 123. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 124. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 125. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 126. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 127. SOUTH KOREA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 128. AUSTRALIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 129. AUSTRALIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 130. AUSTRALIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 131. AUSTRALIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 132. AUSTRALIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 133. THAILAND DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 134. THAILAND DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 135. THAILAND DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 136. THAILAND DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 137. THAILAND DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 138. MALAYSIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 139. MALAYSIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 140. MALAYSIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 141. MALAYSIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 142. MALAYSIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 143. INDONESIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 144. INDONESIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 145. INDONESIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 146. INDONESIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 147. INDONESIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 148. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 149. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 150. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 151. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 152. REST OF ASIA PACIFIC DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 153. LAMEA DISEASE-MODIFYING AGENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 154. LAMEA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 155. LAMEA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 156. LAMEA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 157. LAMEA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 158. LAMEA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 159. BRAZIL DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 160. BRAZIL DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 161. BRAZIL DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 162. BRAZIL DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 163. BRAZIL DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 164. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 165. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 166. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 167. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 168. SOUTH AFRICA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 169. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 170. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 171. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 172. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 173. SAUDI ARABIA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 174. UAE DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 175. UAE DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 176. UAE DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 177. UAE DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 178. UAE DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 179. ARGENTINA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 180. ARGENTINA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 181. ARGENTINA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 182. ARGENTINA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 183. ARGENTINA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 184. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 185. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY INDICATION, 2022-2032 ($MILLION)
TABLE 186. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 187. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 188. REST OF LAMEA DISEASE-MODIFYING AGENTS, BY END USER, 2022-2032 ($MILLION)
TABLE 189. BIOGEN INC.: KEY EXECUTIVES
TABLE 190. BIOGEN INC.: COMPANY SNAPSHOT
TABLE 191. BIOGEN INC.: OPERATING SEGMENTS
TABLE 192. BIOGEN INC.: PRODUCT PORTFOLIO
TABLE 193. BIOGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 194. MERCK KGAA: KEY EXECUTIVES
TABLE 195. MERCK KGAA: COMPANY SNAPSHOT
TABLE 196. MERCK KGAA: OPERATING SEGMENTS
TABLE 197. MERCK KGAA: PRODUCT PORTFOLIO
TABLE 198. MERCK KGAA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 199. ELAN PHARMA INDIA PVT LTD.: KEY EXECUTIVES
TABLE 200. ELAN PHARMA INDIA PVT LTD.: COMPANY SNAPSHOT
TABLE 201. ELAN PHARMA INDIA PVT LTD.: OPERATING SEGMENTS
TABLE 202. ELAN PHARMA INDIA PVT LTD.: PRODUCT PORTFOLIO
TABLE 203. ELAN PHARMA INDIA PVT LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 204. FRESENIUS KABI: KEY EXECUTIVES
TABLE 205. FRESENIUS KABI: COMPANY SNAPSHOT
TABLE 206. FRESENIUS KABI: OPERATING SEGMENTS
TABLE 207. FRESENIUS KABI: PRODUCT PORTFOLIO
TABLE 208. FRESENIUS KABI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 209. PFIZER INC: KEY EXECUTIVES
TABLE 210. PFIZER INC: COMPANY SNAPSHOT
TABLE 211. PFIZER INC: OPERATING SEGMENTS
TABLE 212. PFIZER INC: PRODUCT PORTFOLIO
TABLE 213. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 214. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 215. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 216. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 217. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 218. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 219. HOSPIRA, INC.: KEY EXECUTIVES
TABLE 220. HOSPIRA, INC.: COMPANY SNAPSHOT
TABLE 221. HOSPIRA, INC.: OPERATING SEGMENTS
TABLE 222. HOSPIRA, INC.: PRODUCT PORTFOLIO
TABLE 223. HOSPIRA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 224. ACCORD HEALTHCARE INC: KEY EXECUTIVES
TABLE 225. ACCORD HEALTHCARE INC: COMPANY SNAPSHOT
TABLE 226. ACCORD HEALTHCARE INC: OPERATING SEGMENTS
TABLE 227. ACCORD HEALTHCARE INC: PRODUCT PORTFOLIO
TABLE 228. ACCORD HEALTHCARE INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 229. NORDIC GROUP BV: KEY EXECUTIVES
TABLE 230. NORDIC GROUP BV: COMPANY SNAPSHOT
TABLE 231. NORDIC GROUP BV: OPERATING SEGMENTS
TABLE 232. NORDIC GROUP BV: PRODUCT PORTFOLIO
TABLE 233. NORDIC GROUP BV: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 234. ANTARES PHARMA, INC.: KEY EXECUTIVES
TABLE 235. ANTARES PHARMA, INC.: COMPANY SNAPSHOT
TABLE 236. ANTARES PHARMA, INC.: OPERATING SEGMENTS
TABLE 237. ANTARES PHARMA, INC.: PRODUCT PORTFOLIO
TABLE 238. ANTARES PHARMA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL DISEASE-MODIFYING AGENTS MARKET SEGMENTATION
FIGURE 2. GLOBAL DISEASE-MODIFYING AGENTS MARKET
FIGURE 3. SEGMENTATION DISEASE-MODIFYING AGENTS MARKET
FIGURE 4. TOP INVESTMENT POCKET IN DISEASE-MODIFYING AGENTS MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDISEASE-MODIFYING AGENTS MARKET
FIGURE 11. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY DRUG CLASS
FIGURE 12. DISEASE-MODIFYING AGENTS MARKET FOR INTERFERON BETA-1α/β, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. DISEASE-MODIFYING AGENTS MARKET FOR NATALIZUMAB, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. DISEASE-MODIFYING AGENTS MARKET FOR MITOXANTRONE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 15. DISEASE-MODIFYING AGENTS MARKET FOR GLATIRAMER ACETATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. DISEASE-MODIFYING AGENTS MARKET FOR FINGOLIMOD, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 17. DISEASE-MODIFYING AGENTS MARKET FOR DIMETHYL FUMARATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. DISEASE-MODIFYING AGENTS MARKET FOR OCRELIZUMAB, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. DISEASE-MODIFYING AGENTS MARKET FOR TERIFLUNOMIDE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 20. DISEASE-MODIFYING AGENTS MARKET FOR CICLOSPORIN, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 21. DISEASE-MODIFYING AGENTS MARKET FOR CYCLOPHOSPHAMIDE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. DISEASE-MODIFYING AGENTS MARKET FOR HYDROXYCHLOROQUINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 23. DISEASE-MODIFYING AGENTS MARKET FOR LEFLUNOMIDE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 24. DISEASE-MODIFYING AGENTS MARKET FOR METHOTREXATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 25. DISEASE-MODIFYING AGENTS MARKET FOR MYCOPHENOLATE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 26. DISEASE-MODIFYING AGENTS MARKET FOR SULFASALAZINE, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 27. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 28. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY INDICATION
FIGURE 29. DISEASE-MODIFYING AGENTS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 30. DISEASE-MODIFYING AGENTS MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 31. DISEASE-MODIFYING AGENTS MARKET FOR PSORIATIC ARTHRITIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 32. DISEASE-MODIFYING AGENTS MARKET FOR ANKYLOSING SPONDYLITIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 33. DISEASE-MODIFYING AGENTS MARKET FOR SYSTEMIC SCLEROSIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 34. DISEASE-MODIFYING AGENTS MARKET FOR CANCER, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 35. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 36. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY THERAPY TYPE
FIGURE 37. DISEASE-MODIFYING AGENTS MARKET FOR MONOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 38. DISEASE-MODIFYING AGENTS MARKET FOR COMBINATION THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 39. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
FIGURE 40. DISEASE-MODIFYING AGENTS MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 41. DISEASE-MODIFYING AGENTS MARKET FOR INFUSION, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 42. DISEASE-MODIFYING AGENTS MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 43. DISEASE-MODIFYING AGENTS MARKET FOR INTRAVENOUS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 44. DISEASE-MODIFYING AGENTS MARKET SEGMENTATION, BY BY END USER
FIGURE 45. DISEASE-MODIFYING AGENTS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 46. DISEASE-MODIFYING AGENTS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 47. DISEASE-MODIFYING AGENTS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 48. DISEASE-MODIFYING AGENTS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: DISEASE-MODIFYING AGENTS MARKET
FIGURE 55. Top player positioning, 2022
FIGURE 56. BIOGEN INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. BIOGEN INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 58. BIOGEN INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 59. MERCK KGAA: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. MERCK KGAA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 61. MERCK KGAA: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 62. ELAN PHARMA INDIA PVT LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. ELAN PHARMA INDIA PVT LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 64. ELAN PHARMA INDIA PVT LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 65. FRESENIUS KABI: NET SALES, 2020-2022 ($MILLION)
FIGURE 66. FRESENIUS KABI: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 67. FRESENIUS KABI: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 68. PFIZER INC: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. PFIZER INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 70. PFIZER INC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 73. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 74. HOSPIRA, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 75. HOSPIRA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 76. HOSPIRA, INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 77. ACCORD HEALTHCARE INC: NET SALES, 2020-2022 ($MILLION)
FIGURE 78. ACCORD HEALTHCARE INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 79. ACCORD HEALTHCARE INC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 80. NORDIC GROUP BV: NET SALES, 2020-2022 ($MILLION)
FIGURE 81. NORDIC GROUP BV: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 82. NORDIC GROUP BV: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 83. ANTARES PHARMA, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 84. ANTARES PHARMA, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 85. ANTARES PHARMA, INC.: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Disease-Modifying Agents Market Global Opportunity Analysis and Industry Forecast, 2023-2032

2023

Disease-modifying Agents Market

Disease-Modifying Agents Market

COVID-19

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: DISEASE-MODIFYING AGENTS MARKET, BY DRUG CLASS

4.1. Market Overview

4.1.1 Market Size and Forecast, By Drug Class

4.2. Interferon Beta-1α/β

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Natalizumab

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

4.4. Mitoxantrone

4.4.1. Key Market Trends, Growth Factors and Opportunities

4.4.2. Market Size and Forecast, By Region

4.4.3. Market Share Analysis, By Country

4.5. Glatiramer Acetate

4.5.1. Key Market Trends, Growth Factors and Opportunities

4.5.2. Market Size and Forecast, By Region

4.5.3. Market Share Analysis, By Country

4.6. Fingolimod

4.6.1. Key Market Trends, Growth Factors and Opportunities

4.6.2. Market Size and Forecast, By Region

4.6.3. Market Share Analysis, By Country

4.7. Dimethyl Fumarate

4.7.1. Key Market Trends, Growth Factors and Opportunities

4.7.2. Market Size and Forecast, By Region

4.7.3. Market Share Analysis, By Country

4.8. Ocrelizumab

4.8.1. Key Market Trends, Growth Factors and Opportunities

4.8.2. Market Size and Forecast, By Region

4.8.3. Market Share Analysis, By Country

4.9. Teriflunomide

4.9.1. Key Market Trends, Growth Factors and Opportunities

4.9.2. Market Size and Forecast, By Region

4.9.3. Market Share Analysis, By Country

4.10. Ciclosporin

4.10.1. Key Market Trends, Growth Factors and Opportunities

4.10.2. Market Size and Forecast, By Region

4.10.3. Market Share Analysis, By Country

4.11. Cyclophosphamide

4.11.1. Key Market Trends, Growth Factors and Opportunities

4.11.2. Market Size and Forecast, By Region

4.11.3. Market Share Analysis, By Country

4.12. Hydroxychloroquine

4.12.1. Key Market Trends, Growth Factors and Opportunities

4.12.2. Market Size and Forecast, By Region

4.12.3. Market Share Analysis, By Country

Disease-Modifying Agents Market
Global Opportunity Analysis and Industry Forecast, 2023-2032